Shenzhen Hemogen Gene

Hemogen Gene is a clinical-stage biotechnology company headquartered in Shenzhen, China, dedicated to developing transformative gene therapies for rare genetic blood disorders. The company leverages its proprietary gene editing and viral vector platforms to create one-time curative treatments for conditions such as beta-thalassemia and hemophilia. Its lead program, HMG001, is an autologous CRISPR-edited stem cell therapy currently in clinical trials for transfusion-dependent beta-thalassemia. By targeting the BCL11A enhancer, the therapy aims to reactivate fetal hemoglobin production, potentially freeing patients from chronic transfusion requirements. Hemogen Gene is supported by prominent venture capital firms and maintains state-of-the-art R&D and GMP manufacturing facilities in Shenzhen.